Indivior PLC – NASDAQ:INDV
Indivior stock price today
Indivior stock price monthly change
Indivior stock price quarterly change
Indivior key metrics
Market Cap | 1.47B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIndivior stock price history
Indivior stock forecast
Indivior financial statements
$19
Potential downside: -17.46%
Analysts Price target
Financials & Ratios estimates
| 2023 | 1.09B | 2M | 0.18% |
|---|
| 2024-04-25 | 0.38 | 0.37 |
|---|
| 2017 | 1443999788 | 1.64B | 114.06% |
|---|---|---|---|
| 2023 | 1954000000 | 1.95B | 99.86% |
| 2017 | 309.87M | -45.16M | -88.23M |
|---|---|---|---|
| 2019 | 156.80M | -2.07M | -13.49M |
| 2022 | -3.92M | -218.94M | -98.18M |
| 2023 | -315M | -100.36M | -46M |
Indivior alternative data
| Jun 2024 | 1,000 |
|---|---|
| Jul 2024 | 1,000 |
| Dec 2024 | 1,000 |
Indivior other data
-
What's the price of Indivior stock today?
One share of Indivior stock can currently be purchased for approximately $23.02.
-
When is Indivior's next earnings date?
Unfortunately, Indivior's (INDV) next earnings date is currently unknown.
-
Does Indivior pay dividends?
No, Indivior does not pay dividends.
-
How much money does Indivior make?
Indivior has a market capitalization of 1.47B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 58.48% to 1.09B US dollars. Indivior earned 2M US dollars in net income (profit) last year or $0.37 on an earnings per share basis.
-
What is Indivior's stock symbol?
Indivior PLC is traded on the NASDAQ under the ticker symbol "INDV".
-
What is Indivior's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Indivior?
Shares of Indivior can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Indivior have?
As Dec 2024, Indivior employs 1,000 workers.
-
When Indivior went public?
Indivior PLC is publicly traded company for more then 10 years since IPO on 29 Dec 2014.
-
What is Indivior's official website?
The official website for Indivior is indivior.com.
-
Where are Indivior's headquarters?
Indivior is headquartered at 10710 Midlothian Turnpike, North Chesterfield, VA.
-
How can i contact Indivior?
Indivior's mailing address is 10710 Midlothian Turnpike, North Chesterfield, VA and company can be reached via phone at 804 379 1090.
-
What is Indivior stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Indivior in the last 12 months, the avarage price target is $19. The average price target represents a -17.46% change from the last price of $23.02.
Indivior company profile:
Indivior PLC
indivior.comNASDAQ
1,000
Drug Manufacturers - Specialty & Generic
Healthcare
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
North Chesterfield, VA 23235
CIK: 0001625297
ISIN: GB00BN4HT335
:
